Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

Michael J Joyner, Katelyn A Bruno, Stephen A Klassen, Katie L Kunze, Patrick W Johnson, Elizabeth R Lesser, Chad C Wiggins, Jonathon W Senefeld, Allan M Klompas, David O Hodge, John R A Shepherd, Robert F Rea, Emily R Whelan, Andrew J Clayburn, Matthew R Spiegel, Sarah E Baker, Kathryn F Larson, Juan G Ripoll, Kylie J Andersen, Matthew R Buras, Matthew N P Vogt, Vitaly Herasevich, Joshua J Dennis, Riley J Regimbal, Philippe R Bauer, Janis E Blair, Camille M van Buskirk, Jeffrey L Winters, James R Stubbs, Noud van Helmond, Brian P Butterfield, Matthew A Sexton, Juan C Diaz Soto, Nigel S Paneth, Nicole C Verdun, Peter Marks, Arturo Casadevall, DeLisa Fairweather, Rickey E Carter, R Scott Wright, Michael J Joyner, Katelyn A Bruno, Stephen A Klassen, Katie L Kunze, Patrick W Johnson, Elizabeth R Lesser, Chad C Wiggins, Jonathon W Senefeld, Allan M Klompas, David O Hodge, John R A Shepherd, Robert F Rea, Emily R Whelan, Andrew J Clayburn, Matthew R Spiegel, Sarah E Baker, Kathryn F Larson, Juan G Ripoll, Kylie J Andersen, Matthew R Buras, Matthew N P Vogt, Vitaly Herasevich, Joshua J Dennis, Riley J Regimbal, Philippe R Bauer, Janis E Blair, Camille M van Buskirk, Jeffrey L Winters, James R Stubbs, Noud van Helmond, Brian P Butterfield, Matthew A Sexton, Juan C Diaz Soto, Nigel S Paneth, Nicole C Verdun, Peter Marks, Arturo Casadevall, DeLisa Fairweather, Rickey E Carter, R Scott Wright

Abstract

Objective: To provide an update on key safety metrics after transfusion of convalescent plasma in hospitalized coronavirus 2019 (COVID-19) patients, having previously demonstrated safety in 5000 hospitalized patients.

Patients and methods: From April 3 to June 2, 2020, the US Food and Drug Administration Expanded Access Program for COVID-19 convalescent plasma transfused a convenience sample of 20,000 hospitalized patients with COVID-19 convalescent plasma.

Results: The incidence of all serious adverse events was low; these included transfusion reactions (n=78; <1%), thromboembolic or thrombotic events (n=113; <1%), and cardiac events (n=677, ~3%). Notably, the vast majority of the thromboembolic or thrombotic events (n=75) and cardiac events (n=597) were judged to be unrelated to the plasma transfusion per se. The 7-day mortality rate was 13.0% (12.5%, 13.4%), and was higher among more critically ill patients relative to less ill counterparts, including patients admitted to the intensive care unit versus those not admitted (15.6 vs 9.3%), mechanically ventilated versus not ventilated (18.3% vs 9.9%), and with septic shock or multiple organ dysfunction/failure versus those without dysfunction/failure (21.7% vs 11.5%).

Conclusion: These updated data provide robust evidence that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and support the notion that earlier administration of plasma within the clinical course of COVID-19 is more likely to reduce mortality.

Copyright © 2020. Published by Elsevier Inc.

Figures

Figure 1
Figure 1
Participation in the US COVID-19 Convalescent Plasma Expanded Access Program (EAP) including data extracted on June 11, 2020. Choropleth map displaying the number of cumulatively enrolled patients in the EAP within each state, with lower enrollment values displayed in a lighter hue of green and higher enrollment values displayed in a darker hue of green. Registered acute care facilities are represented as filled yellow circles, with larger circles indicating greater number of registered facilities within the metropolitan area of a city. The choropleth map does not display data from US territories, including registered facilities in Puerto Rico, Guam, and Northern Mariana Islands.
Figure 2
Figure 2
Seven-day mortality rate in patients transfused with COVID-19 convalescent plasma stratified by week since initiation of the US COVID-19 Convalescent Plasma Expanded Access Program (EAP). Each green bar indicates the 7-day mortality rate stratified by the patients enrolled during a given week since the initiation of the EAP.

References

    1. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): cases in US. CDC website. . Accessed August 4, 2020.
    1. Rajgor D.D., Lee M.H., Archuleta S., Bagdasarian N., Quek S.C. The many estimates of the COVID-19 case fatality rate. Lancet Infect Dis. 2020;20(7):776–777.
    1. Wang K., Zhang Z., Yu M., Tao Y., Xie M. 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study. 2020. Intensive Care Med [Epub ahead of print]
    1. Yang X., Yu Y., Xu J. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481.
    1. Richardson S., Hirsch J.S., Narasimhan M. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059.
    1. Bhatraju P.K., Ghassemieh B.J., Nichols M. Covid-19 in critically ill patients in the Seattle region — case series. N Engl J Med. 2020;382(21):2012–2022.
    1. Casadevall A., Pirofski L.A. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–1548.
    1. Zhang J.S., Chen J.T., Liu Y.X. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005;77(2):147–150.
    1. Luke T.C., Kilbane E.M., Jackson J.L., Hoffman S.L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599–609.
    1. Joyner M.J. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. 2020. J Clin Invest.
    1. Wright F.L., Vogler T.O., Moore E.E. Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020 doi: 10.1016/j.jamcollsurg.2020.05.007.
    1. Wichmann D., Sperhake J.P., Lutgehetmann M. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020 doi: 10.7326/M20-2003.
    1. Inciardi R.M., Lupi L., Zaccone G. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 2020 doi: 10.1001/jamacardio.2020.1096.
    1. Harris P.A., Taylor R., Thielke R., Payne J., Gonzalez N., Conde J.G. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
    1. Harris P.A., Taylor R., Minor B.L. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
    1. US Centers for Disease Control and Prevention. The National Healthcare Safety Network (NHSN) Manual . Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases; Atlanta, GA: 2018. (Biovigilance Component v2.5).
    1. Garg S. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 States, March 1–30, 2020. MMWR. 2020;69(15):458–464.
    1. Goyal P., Choi J.J., Pinheiro L.C. Clinical characteristics of COVID-19 in New York City. N Engl J Med. 2020;382(24):2372–2374.
    1. Dzik S. COVID-19 Convalescent Plasma: Now Is the Time for Better Science. Transfus Med Rev. 2020 doi: 10.1016/j.tmrv.2020.04.002.
    1. Klok F.A., Kruip M., van der Meer N.J.M. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148–150.
    1. Giudicessi J.R., Noseworthy P.A., Friedman P.A., Ackerman M.J. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19) Mayo Clinic Proc. 2020;95(6):1213–1221.
    1. Roubinian N. TACO and TRALI: biology, risk factors, and prevention strategies. Hematology Am Soc Hematol Educ Program. 2018;2018(1):585–594.
    1. Bloch E.M., Shoham S., Casadevall A. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–2765.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner